

The PRIVAK status was created by a Royal Decree of 18 April 1997 and is part of a wider raft of measures taken by the Belgian government to boost investment in venture capital. PRIVAKs were initially required to apply for a listing on the Belgian stock exchange, but in May 2003, the regulator granted them the option to remain private, which means that their shareholder structures can be reserved exclusively for private investors. The PRIVAK is obliged to pay out at least 80% of the profits that stem from the realized capital gains of its accounting year.

ONLY TWO BELGIAN PRIVAKS

Quest for Growth and KBC Biotech are currently the only two public PRIVAKs in Belgium. It is unsure that other public PRIVAKs are currently being set up.



The first company to be awarded the PRIVAK status was Quest for Growth, which received the status in 1998. Quest for Growth is focused on investing money in technology and high growth companies and has a clear-cut policy for investments in listed stocks.



The KBC Private Equity Fund Biotech (KBC Biotech) was the second PRIVAK to be launched and was approved in 2001. KBC Biotech has invested exclusively in biotechnology companies. Its investments in listed stakes are mainly done on the Nasdaq stock exchange.

OVERSEEN BY THE CBFA

Companies with PRIVAK status are monitored by the CBFA, the Belgian market regulator. The name PRIVAK is derived from 'Private Equity' and 'Bevak' (closed-end investment company). In essence, a PRIVAK is a Belgian closed-end investment company that provides a framework for private investors to invest directly in admissible financial instruments issued by unlisted companies and growth companies.

INVESTMENT CRITERIA

PRIVAKs are subject to very strict investment criteria and are subject to some constraints concerning dividend payments.

1. At least 50% of the portfolio must be invested in equity.
2. At least 70% of the portfolio must be invested in so-called qualified investments, which are investments in non-quoted companies, companies that are quoted in a growth market or investments in private equity funds with a similar investment profile to the PRIVAK.
3. Investments in companies quoted on a growth market must be limited to 50% of the above-mentioned qualified investments.
4. PRIVAKs may invest no more than 20% of total assets in a single company and must restrict the investments per company per year to a maximum of € 6.2m.

FISCAL BENEFITS

PRIVAKs are granted substantial tax benefits, over and above the exemption from capital gains tax normally granted to Belgian investment vehicles. A PRIVAK's dividends are exempt from withholding tax if at least 80% of the profits stem from realized capital gains and if the company complies with all of the investment criteria. The part of the dividend resulting from capital gains will be exempt from withholding tax, while the remaining part of the dividend will be subject to a withholding tax of 15%.

Description

Quest for Growth is a Belgian investment company focused on listed and unlisted growth companies with the objective of converting capital gains into tax-free income through the Privak-structure.

Investment cases

- Quest's investors benefit from Belgium's Privak statute, thanks to which the gross dividend is net of taxes
- Quest has a dynamically managed portfolio of listed stocks, leaving it vulnerable to the market's momentum
- Quest's unlisted investments have been subject to writedowns against a background of a frozen M&A market
- Our rating is entirely based on valuation grounds, as the stock is trading at relatively high discount levels

Shareholder structure

	# shs	% shs	value (€m)
Dexia Bank	1,393,813	11.82%	6.12
KBC Asset Mgt	574,357	4.87%	2.52
Laxey Partners	1,413,780	11.99%	6.21
Free float	8,407,305	71.31%	36.91

Analyst opinion

Stock price:	€ 4.39
Target price:	€ 5.50
Potential:	20.18%
Rating:	BUY



Company specifics

Market cap:	€ 52m
Currency:	EUR
Avg. daily value:	€ 0.06m
Avg. 3M volume:	6,200
% chg 1M:	-3.09%
% chg 1Y:	22.63%
52-week hi/lo:	4.95 / 3.5
BB-code:	QFG BB
Reuters-code:	QUFG.BR
Web:	www.questforgrowth.com



Corporate calendar

04-Jun-2010	NAV update (A)
02-Jul-2010	NAV update (A)
22-Jul-2010	Results 1H (A)
23-Jul-2010	Analyst Meeting (A)
06-Aug-2010	NAV update (A)
03-Sep-2010	NAV update (A)

Dividend data



Volume and performance data



News flow

23-04-2010: 1Q10 marks 4th consecutive quarterly profit

Quest in 1Q10 booked a € 2.08m profit (€ 0.18 p.s.), marking the 4th consecutive quarterly period that was written in black. The profit compares with a 1Q09 loss of € 2.07m (€ 0.18 p.s.) and FY09 profit of € 18.07m (€ 1.53 p.s.). Quest's monthly NAV updates had already unveiled that equity p.s. at end-1Q10 climbed to € 7.42 p.s., versus € 7.25 at end-FY09 (+2.3% ytd), while the stock decreased to € 4.40 (+5.4% ytd). As a result of the surprisingly negative stock price evolution, the discount narrowed to 40.7% (versus 35.9% at end-FY09). The 2.3% YTD rise of NAV compares with a 12.9% rise of the benchmark Nasdaq index (triggered by the rise of the USD vs. the EUR) and a 6.7% increase of the New Market 50 index. Overall, the first quarter brought little excitement for Quest for Growth. In terms of profitability the listed portfolio (again) accounts for almost all of the result, as the small-cap and speciality investor continued to profit from a sharp increase of specialty stocks (that lagged up until YE09). Earnings contribution from the privately-held portfolio amounted to € 0.2m, but the portfolio's underlying valuation has certainly stabilised; the need to impair valuations has evaporated and peer group valuations have risen on the back of higher economic growth expectations. Quest has also witnessed an improvement in the overall quality of new investment proposals for PE investments, which – coupled with more realistic valuation expectations – could indicate more investment activity further down the road. During 1Q10, Quest's AGM approved the proposed agreement between the company and Quest Management NV. The fee decreased from € 1.9m (€ 0.16 p.s.) to a fixed annual level of € 1.5bn (€ 0.13 p.s.). The agreement kicked in on 1 April 2010 and runs over 12 months. The Global Cost Ratio (all costs carried by QfG versus NAV) will be kept below 3.5 %. Going forward, Quest believes that the economic recovery will persist, even in Europe, but also that the period of bargains on the stock markets, which have taken a head start on future growth, seems to be mostly over. The 1Q10 profit confirms an earlier reported increase in monthly NAV. Despite having closed yet another quarter in the black, Quest's balance sheet still carries € 24.7m of carried-over losses; investors better not bank on the payment of a dividend anytime soon. On the bright side, having taken a number of impairments at the level of the unlisted portfolio in FY09 abides well, as this might have increased the underlying potential and quality of the Private Equity portfolio (both direct and indirect). We estimate adjusted equity value per share at € 7.62 with a dazzling 41.7% discount. Awaiting the outcome of an analyst meeting, scheduled of 11AM today, we stick to our Accumulate rating and € 5.25 TP.

06-04-2010: March update unveils NAV rise of 2.1% m/m

NAV at end-March increased to € 7.42 per share, versus € 7.27 at end-February (+2.1% m/m, +2.3% YTD). The stock hovered more or less steady at € 4.40 (+1.1% m/m, -5.4% YTD), due to which the discount remained level with the end-February reading at 40.70%. Quest made some changes to its listed portfolio, upping stakes in WireCard, Ablynx, Teva Pharmaceuticals and Arcadis and lowering positions in Unit 4 Agresso, EVS and TKH Group. Quest didn't add new investments to the ranks, but sold all of its Téléperformance, Wilex and Solar Millennium shares. Combined, the listed portfolio totals € 57.7m and accounts for 65% of NAV. Listed assets break down in Software & Services (14.9%), Technology & Hardware (11.3%), Pharma & Biotech (4.7%), Healthcare Equipment (2.9%), Electrical & Engineering (17.5%) and Materials (6.1%). Quoted/unquoted assets (i.e. Movetis) account for 7.7% of NAV. The value of the direct Private Equity stakes wasn't subject to changes and there was few to no important activity in the 3rd Party fund portfolio either. The direct and indirect PE portfolios are valued at a respective € 15.6m and € 8.4m. Combined, PE stakes account for € 24.6m, or 28% of adjusted equity. The official NAV figure still hovers south of our NAV estimate, due to a lock-up discount to the Movetis stake that shaves off around € 0.8 p.s. of the official NAV estimate. Our SOTP model, however, applies actual market values. The discount currently stands at 40.1%; we again state that we believe this level to be unjustifiably high for a dynamic investment company such as Quest, despite a broad number of past writedowns in the Private Equity portfolio and the fact that it has few options to create value via exits (IPO or trade sale). Our adjusted equity value estimate amounts to € 7.52, leaving upside potential of 16.6%. Accumulate rating maintained with a € 5.25 target price (30% discount to target equity value).

18-03-2010: Fixed management fee fixed at €1.75m

Quest for Growth at yesterday's AGM announced the details of the adjusted agreement between the company and Quest Management NV. The fee for managing QfG decreases from € 1.9m (€ 0.16 p.s.) to a fixed annual level of € 1.5bn (€ 0.13 p.s.). The agreement kicks in as from 1 April 2010 and runs over 12 months. Both parties agreed to keep the Global Cost Ratio (all costs carried by QfG versus NAV) below 3.5 %. Should the management fee drop below 1.5 % p.a., an adjustment of the agreement will also be considered between both parties. Based on the last published portfolio update (end-February 2010), the fee amounts to 1.75% of NAV (previously: 2.27 %). Going by our current NAV estimate, which is based on yesterday's closing prices and which doesn't include an IPO discount on Movetis, the management fee amounts to 1.69%. But this NAV figure includes 3rd Party Fund investments totalling € 8.4m, on which Quest pays fees of its own, so that in our view the new management fee amounts to 1.97% of "adjusted" NAV and 3.25% of Quest market capitalisation (due to the elevated discount). Even when the 1.75% compares with a list of peers that charge even bulkier fees, we believe this isn't exactly cheap in the framework of remuneration structures of Benelux Holding & Investment companies. As a reminder, QfG's management is also compensated via dividends on its "preferred" stock, an effect that isn't in play now but upon reinstalling dividend flows will kick in as well. We estimate adjusted equity value p.s at € 7.51. The 38.9% discount far from reflects the company's underlying value and in our view is explained by the relatively low liquidity and overall size, as well as by a fairly thinly filled pipeline of exit candidates in the unquoted portfolio. Leaving 14.4% upside potential, our €5.25 TP (which implies a 30% discount) explains our Accumulate rating.

04-03-2010: Few movements in February portfolio and NAV

NAV at end-February hovered steady at € 7.27 per share, versus € 7.29 at end-January (-0.3% m/m, +0.3% YTD). The stock dropped to € 4.35 (-4.0% m/m, -6.5% YTD), due to which the discount increased to 40.17%. Quest made some changes to its listed portfolio, upping stakes in VizRT, United Drug and Vestas Wind Systems and lowering positions in Nemetschek, Téléperformance and EVSVizRT. Quest also added TEVA Pharmaceuticals to the ranks. Combined, the listed portfolio totals € 50.51m and accounts for 57.37% of NAV. Listed assets break down in Software & Services (15.7%), Technology & Hardware (11.0%), Pharma & Biotech (4.05%), Healthcare Equipment (2.8%), Electrical & Engineering (18.1%) and Materials (5.7%). Quoted/unquoted assets account for 8.1% of NAV. The value of the direct Private Equity stakes wasn't subject to changes and there was few to no important activity in the 3rd Party fund portfolio either. The direct and indirect PE portfolios are valued at a respective € 15.9m and € 8.4m. Combined, PE stakes account for € 24.32m of equity, or 27.6%. The official NAV figure hovers south of our NAV estimate, due to a lock-up discount to the Movetis stake that shaves off around € 0.8 p.s. of the official NAV estimate. Our SOTP model, however, applies actual market values. As to the discount, which currently stands at 38.9%, we again state that this level is relatively high for a dynamic investment company such as Quest; we also think it is justified given a long series of writedowns in the Private Equity portfolio and the fact that we see few chances to create value via exits (IPO or trade sale), hence explaining our Accumulate rating. Our adjusted equity value estimate per share based on yesterday's closing prices amounts to € 7.47, leaving upside potential of 15.1%. Accumulate rating maintained with a € 5.25 target price (which implies a 30% discount to target equity value).

04-02-2010: January NAV and stock price hover steady

NAV at end-January climbed to € 7.29 per share, versus € 7.25 at end-December (+0.6% m/m, +28.8% y/y). The stock dropped to € 4.53 (-2.6% m/m, +64.1% y/y), due to which the discount increased slightly to 37.9%. Quest made some changes to its listed portfolio, upping stakes in INIT Innovation in

Please press [here](#) to request a full historical news flow overview of the company

Sum-of-the-parts model





Description	Sector/market	BB	Shares held	Recent change	Last price	Crncy	% of NAV	Valuation (€)
Quoted companies							14.66%	13.52
Software & Services								
INIT	Deutsche Börse	IXX GY	100,000	0	13.8	€	1.49%	1.38
NEMETSCHKE	Deutsche Börse	NEM GR	135,000	0	22.9	€	3.35%	3.09
SELOGER.COM	Euronext Paris	SLG.FP	30,000	-5,000	29.0	€	0.94%	0.87
TRANSICS	Euronext Brussels	TRAN BB	250,000	0	5.9	€	1.60%	1.48
UNIT 4 AGRESSO	Euronext Amsterdam	U4AGR NA	190,330	330	19.1	€	3.94%	3.64
VIZRT	Deutsche Börse	VIZ GR	326,191	0	3.0	€	1.05%	0.97
WIRECARD	Deutsche Börse	WDI GR	250,000	-50,000	8.4	€	2.28%	2.10
Technology Hardware								
EVS BROADCAST	Euronext Brussels	EVS BB	55,000	0	39.7	€	2.37%	2.18
LEM HOLDING	Zwitsersland	LEHN SW	10,000	0	354.8	CHF	2.68%	2.47
TANDBERG	Oslo	TAA NO	140,000	0	169.0	NOK	3.28%	3.03
TKH GROUP	Euronext Amsterdam	TWEKA NA	110,060	-34,745	15.4	€	1.83%	1.69
Pharma & Biotech							11.97%	11.03
ABLYNX	Euronext Brussels	ABLX BB	115,000	0	6.8	€	0.84%	0.78
MOVETIS*	Pharma & Biotech	MOVE BB	523,601	0	12.9	€	7.34%	6.76
ROCHE HOLDINGS	SWX Swiss Exchange	ROG VX	20,000	2,500	165.7	CHF	2.51%	2.31
TEVA PHARMACEUTICAL	Nasdaq	TEVA US	25,000	0	60.6	USD	1.28%	1.18
Health Care Equipment & Svs							2.82%	2.60
UNITED DRUG	Dublin	UGD ID	1,018,628	0	2.6	€	2.82%	2.60
Electrical & Engineering							16.14%	14.89
ANDRITZ	Vienna	ANDR AV	70,000	-10,000	43.8	€	3.33%	3.07
ARCADIS	Euronext Amsterdam	ARCAD NA	235,000	-15,000	16.0	€	4.09%	3.77
FAIVELEY	Euronext Paris	LEY FP	20,000	0	59.5	€	1.29%	1.19
IMTECH	Euronext Brussels	IM NA	77,055	2,055	22.6	€	1.89%	1.74
PFEIFFER VACUUM TECHNO	Deutsche Börse		45,000	5,000	58.0	€	2.83%	2.61
SMA SOLAR	Deutsche Börse	S92 GY	14,000	0	89.5	€	1.36%	1.25
VESTAS WIND SYSTEMS	Copenhagen	VWS DC	30,000	-5,000	313.3	DKK	1.37%	1.26
Materials							5.65%	5.21
CENTROTEC	Deutsche Börse		100,000	5,000	12.3	€	1.33%	1.23
GEBERIT	SWX Swiss Exchange	GEBN VX	12,000	0	177.3	€	1.61%	1.48
UMICORE	Euronext Brussels	UMI BB	100,000	0	25.0	€	2.71%	2.50
Loan notes							1.99%	1.83
Private Equity investments			Asset type	Invested	Committed		26.75%	24.66
ACTIVE CIRCLE	Software & Services	equity		0.40		€	0.43%	0.40
CLEAR2PAY	Software & Services	equity		5.36	0.21	€	5.81%	5.36
COREOPTICS	Technology Hardware	equity		1.41		\$	1.53%	1.41
IDEA	Pharma & Biotech	equity		0.52		€	0.56%	0.52
KIADIS	Pharma & Biotech	equity		2.00		€	2.17%	2.00
MAGWELL	Software & Services	equity		0.43		€	0.47%	0.43
PROSONIX	Pharma & Biotech	equity		1.27		£	1.38%	1.27
SPHERE MEDICAL HOLDING	Pharma & Biotech	equity		1.74		£	1.89%	1.74
SYNTAXIN	Pharma & Biotech	equity		1.77		£	1.91%	1.77
TCLAND	Pharma & Biotech	equity		1.50		€	1.63%	1.50
THIRD PARTY INV FUNDS	Various	Funds		8.26	8.14	€	8.96%	8.26
Portfolio							90.14%	83.12
Net cash (incl. others & options)							9.86%	9.09
Adjusted equity value							100.00%	92.21
Number of shares (outstanding)								11,789,255
Treasury shares (for remuneration purposes, resale, collateral,...)								259,305
Treasury shares (available for cancellation)								0
Number of shares (for per share calculation)								11,789,255
Quest for Growth last price								4.39
Adjusted equity value p.s.								7.82
Current discount								43.87%
Target prices								
Target equity value								92.21
Target equity value p.s.								7.82
Discount to target equity value								43.87%

KBCS has a BUY recommendation and a €5.5 target price.


The upside potential versus a stock price of € 4.39 equals 25.28%.

The implied discount of our € 5.5 target price vs. the target equity value is 29.68%.

Graphical portfolio breakdown



Historical NAV overview



Financial data

Income statement (€m)	04/05	2005	2006	2007	2008	2009
Sales & operating income	0.0	0.0	0.0	0.0	0.0	0.0
Result from operating activities	0.0	0.0	0.0	0.0	0.0	0.0
Result from financing activities	0.0	0.0	0.0	0.0	0.0	0.0
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0	0.0
Share of result of associates	0.0	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Discontinued activities	0.0	0.0	0.0	0.0	0.0	0.0
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
Share of the group	4.6	7.3	21.5	0.6	-48.4	18.1
Adjusted net result	4.6	7.3	21.5	0.6	-48.4	18.1
Balance sheet (€m)	04/05	2005	2006	2007	2008	2009
Intangible assets & goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Tangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Participations acc. for under equity method	0.0	0.0	0.0	0.0	0.0	0.0
Other financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Cash & cash equivalents	0.0	0.0	0.0	0.0	0.0	0.0
Other assets	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL ASSETS	63.8	103.7	117.6	116.5	67.7	85.6
Equity attributable to holders of the parent	63.6	103.2	95.9	115.8	67.4	85.4
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
Financial debt	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL LIABILITIES	63.8	110.6	117.6	116.5	67.7	85.6
net debt	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow statement (€m)	04/05	2005	2006	2007	2008	2009
Cash flow from operating activities	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid (consolidated)	0.0	0.0	0.0	0.0	0.0	0.0
Other cash flow from financing	0.0	0.0	0.0	0.0	0.0	0.0
Fx and changes to consolidation scope	0.0	0.0	0.0	0.0	0.0	0.0
Change in cash & equivalents	0.0	0.0	0.0	0.0	0.0	0.0
Per share data	04/05	2005	2006	2007	2008	2009
Year-end share price (€)	7.9	8.9	10.0	8.4	3.2	4.7
Year-end market cap (€ m)	42.8	84.0	94.6	99.0	37.1	54.8
Weighted average # shares	5,416,000	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
Weighted average # shares, diluted	5,416,000	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
Basic EPS (€)	0.85	0.77	2.28	0.05	-4.11	1.53
Diluted EPS (€)	0.85	0.77	2.28	0.05	-4.11	1.53
NBV (€)	11.7	10.9	10.1	9.8	5.7	7.2
Adjusted equity value (€)	11.7	10.9	12.4	9.9	9.9	7.3
Premium (-) / Discount to (vs. YE stock price)	32.71%	18.61%	19.48%	14.89%	14.89%	35.86%
Gross dividend	0.00	0.69	1.94	0.05	0.00	0.00
Gross dividend yield	0.00%	7.77%	19.40%	0.60%	0.00%	0.00%
Ratios	04/05	2005	2006	2007	2008	2009
Return on Equity (avg)	7.2%	7.0%	22.4%	0.5%	-71.9%	21.2%
Total return	9.7%	21.1%	34.5%	-15.5%	-62.5%	47.6%
Pay-out ratio (adjusted net result)	0.0%	99.9%	100.0%	96.7%	0.0%	0.0%
P/E	9.30	11.58	4.39	159.58	-0.77	3.03
P/NBV	0.67	0.81	0.99	0.86	0.55	0.64
Statutory data (€m)	04/05	2005	2006	2007	2008	2009
Result from operating activities	4.7	7.2	20.7	0.3	-48.6	16.9
Result from financing activities	-0.1	0.1	0.9	0.3	0.2	1.2
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
PROFIT/LOSS FOR THE PERIOD	4.6	7.3	21.5	0.6	-48.4	18.1
Dividends paid (statutory)	0.0	-7.2	-21.5	-0.6	0.0	0.0
Financial assets	63.0	103.2	117.3	116.1	67.1	85.1
Other assets	0.8	0.5	0.3	0.4	0.6	0.5
Capital and reserves	63.6	103.2	95.9	115.8	67.4	85.4
Provisions and deferred taxation	0.0	0.0	0.0	0.0	0.0	0.0
Liabilities	0.2	7.4	21.6	0.7	0.3	0.1
TOTAL ASSETS	63.8	110.6	117.6	116.5	67.7	85.6

Analyst certification: The analysts identified in this report each certify, with respect to the companies or securities that the individual analyses that (i) the views expressed in this publication reflect his or her personal views about the subject companies and securities, and (ii) he or she receives compensation that is based upon various factors, including his or her employer's total revenues, a portion of which are generated by his or her employer's investment banking activities, but not in exchange for expressing the specific recommendation(s) in this report.

This publication has been prepared by KBC Securities NV which is regulated by CBFA (Banking, Finance and Insurance Commission) or one of its European subsidiaries (together "KBC Securities"). This publication is provided for informational purposes only and is not intended to be an offer, or the solicitation of any offer, to buy or sell the securities referred to herein. No part of this publication may be reproduced in any manner without the prior written consent of KBC Securities.

The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but neither KBC Securities nor its affiliates represent that it is accurate or complete, and it should not be relied upon as such. All opinions, forecasts, and estimates herein reflect our judgement on the date of this publication and are subject to change without notice.

From time to time, KBC Securities, its principals or employees may have a position in the securities referred to herein or hold options, warrants or rights with respect thereto or other securities of such issuers and may make a market or otherwise act as principal in transactions in any of these securities. Any such persons may have purchased securities referred to herein for their own account in advance of the release of this publication. KBC Securities and principals or employees of KBC Securities may from time to time provide investment banking or consulting services to, or serve as a director of a company being reported on herein.

This publication is provided solely for the information and use of professional investors who are expected to make their own investment decisions without undue reliance on this publication. Investors must make their own determination of the appropriateness of an investment in any securities referred to herein based on the merits and risks involved, their own investment strategy and their legal, fiscal and financial position. Past performance is no guarantee for future results. By virtue of this publication, none of KBC Securities or any of its employees shall be responsible for any investment decision.

KBC Securities has implemented certain in-house procedures known as Chinese walls that aim to prevent the inappropriate dissemination of inside information. E.g. a Chinese wall surrounds the corporate finance department within KBC Securities. Further measures have been taken with regard to the separation of certain activities that could lead to conflicts of interest with other activities within KBC Securities.

In the United States this publication is being distributed to U.S. Persons by KBC Financial Products USA, Inc., which accepts responsibility for its contents. Orders in any securities referred to herein by any U.S. investor should be placed with KBC Financial Products USA, Inc. and not with any of its foreign affiliates. KBC FP USA Inc. and/or its affiliates may own 1% or more of the subject company's common equity securities. KBCFP USA Inc. or its affiliates may have managed or co-managed a public offering of the subject company's securities in the past 12 months, or received compensation for investment banking services from the subject company in the past 12 months, or expect to receive or intend to seek compensation for investment banking services from the subject company in the next three months. Any U.S. recipient of this report that is not a bank or broker-dealer and that wishes to receive further information regarding, or to effect any transaction in, any security discussed in this report, should contact and place orders with KBC Financial Products USA Inc. This report is being distributed in the United States solely to investors that are (i) "major U.S. institutional investors" (within the meaning of SEC Rule 15a-6 and applicable interpretations relating thereto) that are also "qualified institutional buyers" (QIBs) within the meaning of SEC Rule 144A promulgated by the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Securities Act") or (ii) investors that are not "U.S. Persons" within the meaning of Regulation S under the Securities Act and applicable interpretations relating thereto. The offer or sale of certain securities in the United States may be made to QIBs in reliance on Rule 144A. Such securities may include those offered and sold outside the United States in transactions intended to be exempt from registration pursuant to Regulation S. This report does not constitute in any way an offer or a solicitation of interest in any securities to be offered or sold pursuant to Regulation S. Any such securities may not be offered or sold to U.S. Persons at this time and may be resold to U.S. Persons only if such securities are registered under the Securities Act of 1933, as amended, and applicable state securities laws, or pursuant to an exemption from registration. The products sold by KBC Financial Products USA, Inc or any affiliate thereof, including KBC Securities or KBC Financial Products UK Limited, are not insured by the FDIC, are not obligations of or guaranteed by KBC Bank NV or its affiliates, and are subject to investment risks, including possible loss of the entire amount invested.

This publication is for distribution in or from the United Kingdom only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made thereunder or to investment professionals as defined in Section 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

This publication is for distribution in Canada only to pension funds, mutual funds, banks, asset managers and insurance companies.

The distribution of this publication in other jurisdictions may be restricted by law, and persons into whose possession this publication comes should inform themselves about, and observe, any such restrictions. In particular this publication may not be sent into or distributed, directly or indirectly, in Japan or to any resident thereof.